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Abstract With the recent completion of the International
HapMap Project, many tools are in hand for genetic
association studies seeking to test the common variant/
common disease hypothesis. In contrast, very few tools
and resources are in place for genotype–phenotype
studies hypothesizing that rare variation has a large
impact on the phenotype of interest. To create these tools
for rare variant/common disease studies, much interest is
being generated towards investing in re-sequencing either
large sample sizes of random chromosomes or smaller
sample sizes of patients with extreme phenotypes. As a
case study for rare variant discovery in random chro-
mosomes, we have re-sequenced 1,000 chromosomes
representing diverse populations for the gene C-reactive
protein (CRP). CRP is an important gene in the ﬁelds of
cardiovascular and inﬂammation genetics, and its size
(2 kb) makes it particularly amenable medical or deep
re-sequencing. With these data, we explore several issues
related to the present-day candidate gene association
study including the beneﬁts of complete SNP discovery,
the eﬀects of tagSNP selection across diverse popula-
tions, and completeness of dbSNP for CRP. Also, we
show that while deep re-sequencing uncovers potentially
medically relevant coding SNPs, these SNPs are ﬂeet-
ingly rare when genotyped in a population-based survey
of 7,000 Americans (NHANES III). Collectively, these
data suggest that several diﬀerent types re-sequencing
and genotyping approaches may be required to fully
understand the complete spectrum of alleles that impact
human phenotypes.
Introduction
Since the completion of the Human Genome Project,
much emphasis has been placed on cataloguing human
DNA variation and understanding its impact on
susceptibility to human diseases. The most common
form of sequence polymorphism is the single base
substitution. Single nucleotide polymorphisms (SNPs)
occur on average once every 180 basepairs in the human
genome (Crawford et al. 2005). A catalogue of common
DNA variation is now well-developed in at least one
population (Carlson et al. 2003; Reich et al. 2003), and
new resources provided by the International HapMap
Project (The International HapMap Consortium 2003,
2005) and Perlegen (Hinds et al. 2005), among others,
oﬀer useful information and tools for genetic association
studies for applying common SNPs in diﬀerent popu-
lation samples.
While public databases are useful for mining infor-
mation about common SNPs, the databases are less useful
and complete for rare variants. Rare sequence variants,
deﬁned here as having a minor allele frequency of <1%,
are not well-described most likely because of the number
of chromosomes required to discover them (Kruglyak and
Nickerson 2001). Itis possible that both common and rare
variation will be required to aid investigators in develop-
ing approaches for successful genetic association study
designs. For example, one common design for association
studies, the common disease/common variant approach,
assumes that common DNA variation rather than rare
DNA variation is associated with susceptibility to com-
mon human diseases (Collins et al. 1997). However, many
advocate the possibilitythat many rarevariants, each with
a small contribution, underlie the susceptibility to com-
mon human diseases (Pritchard and Cox 2002). The
arguments are further complicated by study designs that
genotype‘‘tagSNPs’’ andrelyonlinkagedisequilibriumto
identify the causative SNP (‘‘indirect’’) versus genotyping
known nonsynonymous SNPs (‘‘direct’’; Botstein and
Risch 2003).
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on how to obtain rare variation and its application in the
context of a genetic association study are needed in this
age where ‘‘medical’’ re-sequencing is becoming possible
(Gibbs 2005). To provide these data, we have chosen to
examine these issues using the gene C-reactive protein
(CRP). CRP is an ideal model for deep or medical
re-sequencing because it is a small gene (2 kb) whose
protein product is well studied as an established general
marker for predicting cardiovascular disease and risk of
myocardial infarction (Danesh et al. 2004). Further-
more, sequence variation for CRP has been described in
several smaller studies (Brull et al. 2003; Cao and Hegele
2000; Kovacs et al. 2005; Russell et al. 2004; Wolford
et al. 2003), only one of which has identiﬁed nonsyn-
onymous variation within the gene (Miller et al. 2005).
Here, we describe the re-sequencing of a single gene,
CRP, for the purpose of cataloguing both common and
rare variation, and we also describe the possible appli-
cation of the discovered variants in population-based
survey using both ‘‘indirect’’ and ‘‘direct’’ association
study designs. We demonstrate that while deep
re-sequencing or re-sequencing in several racial/ethnic
populations results in the identiﬁcation of rare, poten-
tially damaging nonsynonymous SNPs, the eﬀort may
not necessarily translate to a better understanding of the
gene’s impact on human phenotypes when applied to
larger cohorts linked to quantitative phenotypes.
Materials and methods
Sequencing
As part of NHLBI’s Program for Genomic Applica-
tions, SeattleSNPs re-sequences genes involved in
inﬂammation, lipid metabolism, and blood pressure
regulation for genetic variation discovery in two popu-
lation samples: European-Americans (n=23) and
African-Americans (n=24) obtained from Coriell Cell
Repository. The European-American samples are
members of the CEPH panel (NA12560, NA12547,
NA10845, NA10853, NA10860, NA10830, NA10842,
NA10851, NA07349, NA10857, NA10858, NA10848,
NA12548, NA10844, NA10854, NA10861, NA10831,
NA10843, NA10850, NA07348, NA10852, NA06990,
NA07019) and the African-American samples are
members of the African-American panel of 50
(NA17101-NA17116; NA17133-NA17140). Additional
sequencing for variation discovery was performed on
samples from the Polymorphism Discovery Resource
Panel (PDR450)(Collins et al. 1998) and several
other population samples obtained from Coriell Cell
Repository, including seven Chinese (NA16654,
NA16688-NA16689, NA17014-NA17017), seven Japanese
(NA17051-NA17057), ten Southeast Asians (NA17081-
NA17090), ten Mexicans (NA17061-NA17070), and six
Indo-Pakistanis (NA17021-NA17024; NA17026-NA17027).
All samples were re-sequenced for variation discovery
in CRP on an ABI3730 using standard Big Dye termi-
nator chemistry. A detailed laboratory protocol can be
found on the SeattleSNPs website (see Websites). A total
of 6.8 kb was re-sequenced for CRP, including all exons,
all introns, 1.7 kb 5¢ ﬂanking, and 2.8 kb 3¢ ﬂanking.
SNPs were numbered based on the GenBank accession
number AF449713 and were submitted to dbSNP. The
SNP number does not correspond with the translation
start site. The location, rs number (where available), and
sequence context of the SNPs described here can be
found in Supplementary Table 1. All SNP allele fre-
quencies and 95% conﬁdence intervals for each popu-
lation sample are given in Supplementary Table 2.
Haplotypes were inferred using PHASEv2.1.1 (Stephens
et al. 2001; Stephens and Donnelly 2003) using SNPs
with a minor allele frequency of >5%. Inferred haplo-
types and their counts are given in Supplementary Table
3 for each population sample. TagSNPs were deter-
mined using LDSelect with a minor allele frequency
>5% and r
2>0.64 (Carlson et al. 2004). The predicted
eﬀects of all nonsynonymous variation were explored
computationally using PolyPhen (Ramensky et al. 2002)
and SIFT (Ng and Henikoﬀ 2002).
Genotyping
Standard TaqMan
  Assays by Design
  were developed
to genotype two sites newly discovered in CRP: 2513
and 2612. The sequence for the primers and Taqman
 
probes for 2513 was 5¢-GATCGTGGAGTTCTGGG
TAGATG-3¢ (forward), 5¢-ACAGTGTATCCCTTCT
TCAGACTCT-3¢ (reverse), 5¢-CACCCTGGGCTTC-3¢
(C allele probe), and 5¢-TCACCCTGAGCTTC-3¢
(T allele probe). For 2612, the primers and probes were
5¢-GGGCAGGAGCAGGATTCC-3¢ (forward), 5¢-AG
TCCCACATGTTCACATTTCCAAT-3¢ (reverse), 5¢-AC
TTTGAAGGAAGCCAG-3¢ (G allele probe), and
5¢-ACTTTGAAGAAAGCCAG-3¢ (A allele probe). The
two assays were validated, and individuals identiﬁed as
heterozygous for 2612 were conﬁrmed by re-sequencing.
DNA samples (n=7,296) from the National Health
and Nutrition Examination Survey (NHANES) III were
genotyped for the two sites by Taqman
 . The genotyp-
ing success rate was 97% for both SNPs. NHANES III
is a population-based sample of Americans collected
regardless of health status between 1988 and 1994,
and DNA was collected for phase 2 of the survey
(1991–1994). All DNA samples are linked to an exten-
sive collection of laboratory phenotypes, such as serum
CRP levels, as well as survey data. Survey design and
ascertainment of NHANES III as well as descriptions of
the phenotypic variables can be found at CDC’s
National Center for Health Statistics website (see
Websites). The three largest racial/ethnic groups for
NHANES III include non-Hispanic whites (n=2,630),
non-Hispanic blacks (n=2,108), and Mexican-Americans
(n=2,073). A small number of samples (n=137) were
497duplicates or not linked to the phenotypic data and were
not included in subsequent analyses.
Results
SNP discovery
Three sets of population samples were re-sequenced for
variation discovery in CRP with diﬀerent goals: (1) the
standard SeattleSNPs population samples re-sequenced
for mostly common variation discovery in European-
Americans (n=23) and African-Americans (n=24); (2)
an extended DNA panel of Asians (Chinese, n=7;
Japanese, n=7, Southeast Asian, n=10), Mexicans
(n=10), and Indo-Pakistanis (n=6) for population-
speciﬁc variation discovery; and (3) the Polymorphism
Discovery Resource Panel (PDR; n=450) for rare
coding variation discovery (Collins et al. 1998). Both the
SeattleSNPs and extended DNA panels have suﬃcient
power to identify common SNPs (minor allele frequency
>5%); however, the range of power depends on the
number of chromosomes re-sequenced for each popu-
lation sample. Thus, the African-American and
combined Asian samples have the highest detection
rate for common SNPs (99%), and the Indo-Pakistani
sample has the lowest detect rate for common SNPs
(>80%)(Kruglyak and Nickerson 2001). The PDR can
detect 99% of SNPs with a MAF of at least 1%
(Kruglyak and Nickerson 2001).
To determine whether SeattleSNPs is capturing all
CRP common variation found in many populations by
re-sequencing only European- and African-American
samples, we compared the SNPs identiﬁed by the usual
SeattleSNPs DNA panel to the extended DNA panel
containing samples of Asian, Mexican, and Indo-Paki-
stani ancestry. From these two DNA panels, a total of
40 SNPs were identiﬁed (Fig. 1 and Table 1). As
expected, a greater number of SNPs was identiﬁed in the
African-American population sample (30) compared
with the Asian (17), Mexican (13), European-American
(13), and Indo-Pakistani (11) population samples
(Table 1). Also, an increase in nucleotide diversity as
well as a greater number of haplotypes was observed in
the African-American population samples compared
with the other population samples (Table 1). Approxi-
mately half (58%) of the 40 SNPs are private to one
population sample, most of which were found in the
African-American population sample (14 SNPs). The
inclusion of the extended DNA panel allowed the iden-
tiﬁcation of nine SNPs not identiﬁed in the SeattleSNPs
panel. Two of the nine new sites were common (>5%
MAF) within the Indo-Pakistani population sample
(sites 974 and 2513).
Among the 40 SNPs identiﬁed in CRP, one unique
variant is the high frequency triallelic SNP 1440
(rs3091244). All three alleles of 1440, A, C, and T, occur
with appreciable frequency in the African-American
(0.33, 0.26, and 0.41) and European-American (0.05,
0.62, and 0.33) population samples. Examination of the
extended DNA panel reveals that the combined Asian
population sample of Chinese, Japanese, and Southeast
Asian samples is also polymorphic for all three 1440
alleles (0.19, 0.75, and 0.06); however, the allele fre-
quency distribution in the combined Asian population
sample is very diﬀerent compared with the African- and
European-American population samples. The Mexican
population sample does not contain all three alleles,
possibly due to the smaller sample size of this collection
compared with the other three population samples.
Among chromosomes of Mexican-descent, the C allele
occurs more frequently (0.75) than the T allele. Finally,
among the Indo-Pakistani samples, the C allele is
predominant over the A allele (0.83 vs. 0.17). Again, the
absence of the third allele (T) may be due to the small
sample size of this population collection compared with
the larger collections.
Coding variation
One of the sites identiﬁed in the Indo-Pakistani sample,
SNP 2513 (MAF=0.08), is a nonsynonymous SNP
(Pro133Lys) in exon 2 of CRP. Site 2513 is predicted to
be ‘‘possibly damaging’’ by PolyPhen but ‘‘tolerated’’ by
SIFT (Table 2a). Also, site 2475 identiﬁed in two
heterozygous individuals from the Japanese population
sample is a novel synonymous SNP in exon 2 (Table 2a).
Given the possibility that CRP contains previously
unidentiﬁed rare and potentially population-speciﬁc
nonsynonymous SNPs, we re-sequenced CRP in indi-
viduals from the Polymorphism Discovery Resource
Panel (PDR450) primarily to discover novel coding
variation. The PDR450 samples are not linked to racial/
ethnic identiﬁers; therefore, the panel is useful for DNA
variation discovery, but not for allele frequency esti-
mation for speciﬁc populations. Overall, 46 sites were
identiﬁed in the PDR, 61% of which were not found
Table 1 Sample size
(chromosomes), number of
segregating sites (S), nucleotide
diversity (h), and number of
inferred haplotypes for CRP
re-sequenced in several samples
Sample NS (MAF>5%) h (10
4) Haplotypes (heterozygosity)
African-Americans 48 30 (18) 11.96 18 (0.86)
European-Americans 46 13 (10) 5.25 7 (0.76)
Asians 48 17 (9) 6.84 11 (0.67)
Mexicans 20 13 (11) 6.32 6 (0.74)
Indo-Pakistanis 12 11 (11) 7.17 6 (0.75)
Total 174 40 (17) 11.83 29 (0.86)
498among the SeattleSNPs and extended DNA panel samples.
All novel sites in the PDR had a minor allele frequency
of 2% or less (Supplementary Table 2). Among these
novel sites, we identiﬁed two additional nonsynonymous
SNPs, sites 2314 (Tyr67His) and 2612 (Gly166Glu), each
in a single heterozygous individual. Site 2314 is predicted
Fig. 1 CRP variants identiﬁed
re-sequencing the SeattleSNPs
(n=47) and extended DNA
panels (n=40). SNPs are
numbered across the top of the
ﬁgure in order of discovery in
the reference sequence.
Individual samples are labeled
to the left of the ﬁgure. Each
square represents the genotype
of a SNP for each individual:
homozygous common (blue),
heterozygous (red), and
homozygous rare (yellow).
Gray represents missing data.
Abbreviations: African-
American (D), European-
American (E), extended panel
DNA (V31-36: Indo-Pakistani,
V80-89: Mexican; and V71-77,
V130-139, V321-327: Asian)
499to be tolerated/benign and site 2612 is predicted to be
tolerated/possibly damaging by SIFT and PolyPhen,
respectively (Table 2a). A previously described (site
2667) as well as two novel synonymous SNPs (sites 2220
and 2244) was also identiﬁed in the PDR (Table 2b).
Not surprisingly, the synonymous sites, unlike the
nonsynonymous sites, were identiﬁed in more than one
individual. The nonsynonymous site 2513 and the
synonymous site 2475 identiﬁed in the Indo-Pakistani
and Japanese samples, respectively, were not identiﬁed
in the larger PDR sample. We could not conﬁrm the
recently reported nonsynonymous Thr45Met in any of
the populations re-sequenced here (Miller et al. 2005).
The newly identiﬁed nonsynonymous SNPs are of
obvious interest to investigators designing direct genetic
association studies because it is assumed that these SNPs
are more likely to have a direct impact on the phenotype
than noncoding SNPs (Botstein and Risch 2003).
However, nonsynonymous SNPs are only informative if
they occur at an appreciable frequency in the general
population or are enriched among individuals with
speciﬁc diseases/outcomes. To better characterize the
allele and genotype frequency of the possibly damaging
nonsynonymous SNPs in a general population, we
genotyped sites 2513 and 2612 in a sample of 7,296
DNAs collected by the Centers for Disease Control and
Prevention for phase 2 of the National Health and
Nutrition Examination Survey (NHANES) III. In
>14,000 chromosomes examined, no individual was
heterozygous for site 2513. For site 2612, we identiﬁed
two heterozygous individuals. Thus, these two sites are
rare in the general population with a minor allele
frequency well below 1%.
CRP and dbSNP
For both direct and indirect association study designs,
one common concern for investigators is the reliance on
public databases for available genetic variations in the
gene or region of interest. Previous work examining the
quality and completeness of dbSNP suggests that >50%
of the reported SNPs are common (Carlson et al. 2003;
Jiang et al. 2003; Reich et al. 2003). These studies also
demonstrate that a considerable fraction of SNPs in
dbSNP (40%) cannot be found in other samples,
suggesting these reported SNPs are either very rare or
artifacts (Carlson et al. 2003; Jiang et al. 2003). To
examine these issues for CRP, we mapped the SNPs
identiﬁed here by deep re-sequencing to those found
within dbSNP in the gene CRP.
For build 125 of dbSNP, 17 DNA variations are
reported in the gene CRP. Five of the 17 DNA
variations reported by dbSNP are considered validated
SNPs. To directly compare SNPs reported in dbSNP to
the SNPs discovered in the various populations reported
here, we only considered the 21 SNPs we annotated in
exons 1 and 2 and intron 1. Only six of the 17 dbSNP
reports (35%) can be conﬁrmed by the re-sequencing
eﬀorts described here, and all six of these SNPs were
common SNPs reported by SeattleSNPs. These six SNPs
included the ﬁve validated SNPs. More than half of the
dbSNP submissions (11/17; 64.7%) cannot be conﬁrmed
by any of the populations re-sequenced here. Overall,
71.4% of the CRP variants identiﬁed here are not
currently found in dbSNP; however, none of these SNPs
is common among the chromosomes re-sequenced
here. Thus, dbSNP is most likely complete for common
variation but incomplete for rare variation in CRP,a s
expected.
TagSNPs for association studies
Another common concern for investigators is that an
optimal subset of SNPs (termed ‘‘tagSNPs’’) must be
chosen from the information at hand for genotyping in a
genetic association study. The tagSNP or ‘‘indirect’’
approach can be an economical approach because only
SNPs that maintain the genetic diversity of the gene or
region (as deﬁned by linkage disequilibrium) are geno-
typed (Carlson et al. 2004; Stram 2004). Recent evidence
suggests that tagSNPs are transferable across popula-
tions of similar race/ethnicity without loss of informa-
Table 2 CRP variants identiﬁed in the coding region
Site Nucleotide change Amino acid
change (position)
Number of
chromosomes (panel)
SIFT/PolyPhen
prediction
(a) Nonsynonymous
2314 T > C Tyr to His (67) 1/794 (PDR) Tolerated/benign
2513 C > T Pro to Lys (133) 1/80 (extended) Tolerated/possibly damaging
2612 G > A Gly to Glu (166) 1/828 (PDR) Tolerated/possibly damaging
(b) Synonymous
2220 T > G Thr to Thr (35) 7/700 (PDR) N/A
2244 G > A Pro to Pro (43) 3/734 (PDR) N/A
2475 C > T Ser to Ser (120) 2/80 (extended) N/A
2667 (rs1800947) G > C Leu to Leu (184) 36/826 (PDR) N/A
PDR Polymorphism Discovery Resource panel
500tion (Ke et al. 2004). SeattleSNPs routinely chooses
tagSNPs for European-American and African-American
population samples, and it is expected that these
tagSNPs will be suﬃcient for association studies
genotyping samples of European- and African-descent.
However, it is not know how well these tagSNPs per-
form when genotyped in an admixed population such as
Mexican-Americans.
Previous admixture studies suggest that Mexican or
Mexican-American populations have European, Afri-
can, and Asian/Amerindian ancestry, with proportions
estimated at approximately 40–60, 3–5, and 30–50%,
respectively (Hanis et al. 1991; Long et al. 1991; Collins-
Schramm et al. 2004; Salari et al. 2005). To understand
how much, if any, diversity information is lost in
genotyping SeattleSNPs tagSNPs in a Mexican or
Mexican-American sample, we compared tagSNPs
determined for a combined population of African- and
European-Americans (Fig. 2a, b) to those determined
for the Mexican population sample (Fig. 2c) using
LDSelect at MAF>5% and r
2>0.64. For the Mexican
population sample of 20 chromosomes, ﬁve tagSNPs
were identiﬁed for genotyping. All ﬁve tagSNPs
were represented among tagSNPs chosen for the
Fig. 2 TagSNPs chosen for
four population samples.
TagSNPs were chosen from
SNPs with MAF >5% using
LDSelect at r
2>0.64
501European- and African-American combined sample and
are suﬃcient to capture the genetic diversity of the locus
within the Mexican population sample. Interestingly, the
Asian population sample of Chinese, Japanese, and
Southeastern Asians is also well represented by CRP
tagSNPs chosen from a combined European- and
African-American population sample (Fig. 2d).
Conclusions
By re-sequencing 1,000 chromosomes ascertained from
several population samples, we have catalogued novel
coding and noncoding DNA variants in CRP. The vast
majority of these novel SNPs were rare, consistent
with previous observations from candidate gene deep
re-sequencing projects (Glatt et al. 2001). We also
identiﬁed common CRP variation in the Asian and
Mexican-descent population samples that overlapped to
a great extent with common variation identiﬁed by
SeattleSNPs in the European-American and African-
American population samples.
For CRP-speciﬁc genetic association studies, these
r e - s e q u e n c i n gd a t as u g g e s tt h a tCRP common SNPs
are in dbSNP and that common disease/common
variant study designs using a tagSNP approach can be
applied to several population samples with very little
population-speciﬁc modiﬁcation. That is, if the most
diverse population (e.g., African-descent populations)
is considered in tagSNP selection for CRP, genetic
diversity for CRP in other population samples will be
well represented. However, if only a less diverse
population were considered for tagSNP selection
(e.g., European-descent populations), one tagSNP
(rs3093058) associated with serum CRP levels (Carlson
et al. 2005; D. C. Crawford et al., submitted) would not
be represented for CRP diversity observed in African-
Americans and Mexican-Americans. This issue should
be considered when designing genetic association
studies in non-European population samples using
public SNP resources such as HapMap or dbSNP
(Clark et al. 2005).
The re-sequencing data for CRP also suggest
that coding variation, if not identiﬁed in a small
re-sequencing sample, is very rare in the general popu-
lation. These results are not entirely unexpected because
the samples sizes used in variation discovery for the
present study are based on population genetics theory
(i.e., eﬀective population size and mutation rate) and are
designed to suﬃciently estimate the allele frequency for
SNPs with a minor allele frequency of >5–10%
(Kruglyak and Nickerson 2001). Indeed, tagSNPs
determined in SeattleSNPs were recently genotyped in
three larger studies and demonstrated that allele fre-
quencies estimated in the SeattleSNPs sample of 47
individuals is nearly identical to the allele frequencies
estimated in the larger studies (Carlson et al. 2005;D .C .
Crawford et al., submitted; L. A. Lange et al., in
preparation).
While the coding variation identiﬁed in the present
study was rare in the general population, there is a
possibility that CRP coding variation is strongly
associated with a phenotype and could be enriched in a
case population. The challenge, of course, is to predict a
disease or extreme phenotype given that a putative
mutation has been identiﬁed. Given that the non-
synonymous SNP in CRP may be damaging to the gene
product, we may expect lower levels of serum CRP in
heterozygous individuals compared with homozygous
individuals for the common allele. Alternately, we may
expect individuals heterozygous for these SNPs are
unable to mount a proper acute phase response com-
pared with individuals homozygous for the common
allele. There is no known human deﬁciency for CRP, but
there are several phenotypes associated with lack of
acute phase response (reviewed in Pepys and Hirschﬁeld
2003). Unfortunately, the CRP assay used in NHANES
III is not as sensitive compared with currently used
assays (Centers for Disease Control and Prevention
1994), so we cannot determine how low the serum CRP
levels are for the two individuals who are heterozygous
for the nonsynonymous CRP SNP (D. C. Crawford
et al., submitted).
The possibility that deleterious variation may exist in
human CRP is intriguing. In addition to providing
information for future functional CRP studies in
humans, these deep re-sequencing data provide an
opportunity to explore the eﬀects of possibly deleterious
genetic variation using model organisms and in vitro
assays. One obvious choice for modeling SNP eﬀects in
context with various environmental exposures is the
mouse (MacAuley and Ladiges 2005). However, for
CRP, the mouse is not an ideal model because its CRP
gene does not function like the human CRP gene (Pepys
and Hirschﬁeld 2003). Nevertheless, the CRP example
demonstrates the potential usefulness of identifying
coding variants through deep re-sequencing that may be
taken forward into other meaningful experiments that
specialize in function.
In summary, we describe here the genetic architecture
of CRP with special emphasis on the detection and
characterization of rare variants. While we were able to
describe novel nonsynonymous variants for CRP,w e
were unable to describe these variants at an appreciable
frequency when genotyped in the general population
making it impossible to explore the impact of these
variants on serum CRP. Given this situation, for a
quantitative trait such as CRP, it may be more eﬃcient
to re-sequence individuals at the extreme low and high
end of the distribution in the search for rarer SNPs that
impact the phenotype of interest (Cohen et al. 2005;
Cohen et al. 2004). In the age of more eﬃcient, high
throughput genotyping (Hinds et al. 2004; Shen et al.
2005), it may be that re-sequencing used in conjunction
with genotyping using diﬀerent study designs is required
to fully appreciate the spectrum of genetic variants
associated with a human phenotype of interest.
502Websites
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PolyPhen: http://www.tux.embl-heidelberg.de/ramensky/
SeattleSNPs Program for Genomic Applications:
http://www.pga.gs.washington.edu/
SIFT: http://www.blocks.fhcrc.org/sift/SIFT_BLink_
submit.html
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